2022.02.28 MediciNova Announces MN-166 (ibudilast) Identified as Potential Beneficial Pharmacotherapy for Treatment of Degenerative Cervical Myelopathy in Global Spine Journal DCMMN-166treatise
2019.05.08 MediciNova Participated in the RECEDE Phase 3 Degenerative Cervical Myelopathy Trial Kick-off Meeting, DCM Symposium and the Official Launch of Myelopathy.org in London, United Kingdom DCMMN-166clinical trials
2018.08.07 MN-166のDegenerative Cervical Myelopathy (変性性頸椎脊椎症)を対象とする ケンブリッジ大学とのフェーズ２/３共同臨床治験の開始のお知らせ ～イギリス国立疾病研究センター National Institute for Health Research (NIHR) からの臨床研究助成金をうけて～ DCMMN-166clinical trials
